bipolar disorder
play

Bipolar disorder Paul Harrison Warneford Hospital Bipolar disorder guidelines NICE (2014) British Association for Psychopharmacology (Goodwin et al, 2016, J. Psychopharmacol . 30: 495-553) Covers all aspects Independent

0 downloads 5 Views 459 KB Size Report
  1. Bipolar disorder Paul Harrison Warneford Hospital

  2. Bipolar disorder guidelines • NICE (2014) • British Association for Psychopharmacology (Goodwin et al, 2016, J. Psychopharmacol . 30: 495-553) – Covers all aspects – Independent – Available free from website: https://www.bap.org.uk/guidelines • Also BAP guidelines for psychotropic prescribing in pregnancy/breastfeeding (2017), and off-label prescribing (2017)

  3. Troublesome terms • Mania vs hypomania – Mania = mood elevation etc, with functional impairment. – Hypomania = mood elevation (and increased energy) unequivocal, but it does not cause marked functional impairment – Both need to be present for 7 days (though DSM-5 requires only 4 days for hypomania) • Bipolar I vs Bipolar II – American (DSM) terms – BD1 = ‘true’ BD, with mania – BD2 = milder BD, with hypomania (and depression).

  4. Majority of BD presents with one or more depressive episodes first, so how to spot BD? • Screening for undiagnosed past hypomania – Episode(s) of increased energy/disinhibition/reduced sleep/grandiosity/irritability – Out-of-character/caused problems/regretted – How long? – Was patient on an antidepressant/stimulant at the time? • Family history of BD

  5. • Differential diagnosis – Borderline PD (emotionally unstable PD) – Cyclothymia – ‘Organic’ bipolar disorder • Especially if onset >40, unexpected • Steroids, L-DOPA, thyroid, cortical lesions – Schizoaffective disorder – (A ‘degree’ of BD) • Comorbidities/confounders – The rule not the exception – Alcohol and drugs – Anxiety disorders • Often persistent, and not explained by mood

  6. BD vs borderline PD (BPD) • Distinguishing features of BPD – Personality not illness – Pervasive efforts to avoid abandonment – Features fluctuate in response to relationships, e.g. ‘acting out’ and anger – Chronic feeling of emptiness, depressive symptoms, poor self-image – Absence of true hypomanic episodes – (Differences in characteristics of mood instability) • Comorbid in 20% – Worse outcomes – BPD ‘blinds clinician to diagnosis of BD’ (and its therapy) – Presence of BPD increases case for psychotherapy

  7. Bipolar depression • Causes far more morbidity than the manic phase • SSRIs (and other antidepressants) are largely ineffective and may precipitate hypomania or rapid cycling • Hence recognition of bipolarity is important, as leads to different treatment algorithm • Clinically similar to unipolar depression, but – Melancholic, psychotic, or atypical features raise suspicion – Plus family history and past history mentioned earlier

  8. Drug treatment of bipolar depression First Olanzapine Fluoxetine + Quetiapine line olanzapine Second Fluoxetine + Quetiapine Lamotrigine Quetiapine + line olanzapine lamotrigine

  9. Bipolar depression (2) • Quetiapine: – Strong evidence – (A bit) less weight gain/metabolic syndrome than olanzapine – Anxiety and sedation – Dose varies widely • Start low, warn about sedation • Often <300mg/d needed

  10. Bipolar depression (3) • Lamotrigine – Reasonable effect as sole agent – Useful adjunct if first-line Rx ineffective – Well tolerated – But slow titration, risk of Stevens-Johnson syndrome – CHC • Reduces lamotrigine levels (so risks of toxicity in pill-free week) • Either avoid CHC, or use continuous regimen

  11. Lamotrigine augments quetiapine in bipolar depression Weeks Effective over 12 months: 36% in remission, vs 16% in placebo group NB: Lamotrigine response impaired by folic acid Lancet Psychiatry 2016:3:31-39

  12. Psychosocial aspects of BD • Psychoeducation – Identify triggers – Recognise early signs – Early intervention (e.g. sleep hygiene, hypnotics) – Importance of medication, and compliance – Involve family • Lifestyle advice – Regular routines, avoid drugs and alcohol • Other formal psychotherapies – Little evidence (including for CBT)

  13. Drug treatment of bipolar depression Fluoxetine + First line Olanzapine Quetiapine olanzapine Second line Fluoxetine + Quetiapine Lamotrigine Quetiapine + olanzapine lamotrigine Third Lurasidone (not licensed for BD in UK) line Aripiprazole (resistant cases) Add valproate Add lithium ECT NB: Limited evidence for all compared to unipolar depression

  14. Prophylaxis • Consider after a single manic episode, and definitely after two • Lithium – remains first line – Anti-suicidal effect • Valproate • Lithium + valproate • Quetiapine • Lamotrigine – Not good anti-manic • Carbamazepine – weak evidence, now rarely used • Stopping prophylaxis: difficult decision, often better to continue – Always taper very gradually (especially lithium) • Naturalistic data interesting…

  15. 18,000 BD patients followed for 25 years 9,000 admissions JAMA Psychiatry AOL 28.2.18

  16. Overall, lithium did best

  17. Quetiapine had only modest benefits – and olanzapine none

  18. Depot antipsychotics did much better than oral …compliance

  19. BD in women of child-bearing age • Pros and cons of meds vs no meds, and which one • High risk of relapse during and after pregnancy • BD itself associated with increased risk of adverse pregnancy outcomes • Ideally, discussion and monitoring pre-conception • Avoid valproate • Lithium – less risky than thought – cardiac malformations in 2.4% vs 1.2% • Lamotrigine, quetiapine, olanzapine – relatively safe – as is lithium after first trimester

  20. Physical health monitoring • Same excess mortality and cardiovascular risks as schizophrenia • Physical health checks recommended for mood stabilisers as for antipsychotics • Lithium monitoring (levels, renal, thyroid, calcium) • Guidelines and protocols for both are under review

  21. Services for BD • BD omitted from NSF – Significance and needs neglected – Refer to AMHT or EIS in usual way • Specialist BD clinic run at Warneford by academic psychiatrists – For research studies, especially clinical trials – Remote mood monitoring – Not an emergency service; not complex or chronic cases – Referrals/queries to oxfordhealth.bipolarclinic@nhs.net – Leaflets

  22. https://oxfordhealth.truecolours.nhs.uk/www/

  23. Questions?

  24. Lester UK adaptation (2014) RCPsych

Recommend Documents


bipolar disorder
Bipolar Disorder By: Cassie Schroer

Bipolar Disorder By: Cassie Schroer Bipolar disorder, formerly called

tangible interventions for treating
Tangible Interventions for Treating

Tangible Interventions for Treating Clients with Bipolar Disorder By:

bipolar disorder sleep and cognition bipolar disorder
Bipolar disorder, sleep and cognition

Bipolar disorder, sleep and cognition Bipolar disorder, sleep and cognition

pediatric bipolar disorder
Pediatric Bipolar Disorder 1

3/17/2014 Pediatric Bipolar Disorder 1 3/17/2014 Highlighted Topics Review

bipolar disorder
Bipolar Disorder Roscoe Brady M.D.,

Bipolar Disorder Roscoe Brady M.D., Ph.D. Matcheri Keshavan M.D. Bipolar

what s new in the pharmacological treatment of bipolar
Whats new in the pharmacological

Whats new in the pharmacological treatment of bipolar disorder? Dr. David

bipolar disorder
Bipolar Disorder Kirsten Brandner

Bipolar Disorder Kirsten Brandner Presentation on January 20, 2016 Forensic

the one with treatment resistant bipolar disorder
THE ONE WITH TREATMENT RESISTANT

THE ONE WITH TREATMENT RESISTANT BIPOLAR DISORDER TYLER ZAHRLI MD, MA (PGY-2)

challenges in the management of bipolar disorder learning
CHALLENGES IN THE MANAGEMENT OF BIPOLAR

CHALLENGES IN THE MANAGEMENT OF BIPOLAR DISORDER Learning Objectives

bipolar disorder
Bipolar Disorder 2. Pharmacologic

Overview Bipolar Disorder Solving Clinical Challenges 1. Diagnostic Nosology

primary care mental
Primary Care Mental Head of Clinic of

Christos Lionis Professor of General Practice and Primary Care Primary Care

contact charles triano forest laboratories tel 212 224
Contact: Charles Triano Forest

T~ Contact: Charles Triano Forest Laboratories Tel, (212) 224-6714

major depressive disorder workgroup
Major Depressive Disorder Workgroup

Major Depressive Disorder Workgroup Morning Session 1 Introduction: Chair

depression management
Depression Management Ulka Agarwal,

Depression Management Ulka Agarwal, M.D. Adjunct Psychiatrist Pine Rest

approaches to
Approaches to Quality Sleep Culture

Approaches to Quality Sleep Culture in LTC Sponsored by the Quality

the place for treatments of associated neuropsychiatric
The Place for Treatments of Associated

The Place for Treatments of Associated Neuropsychiatric and Other Symptoms in

brain health
Brain Health Chair: Kirk Erickson

Meeting 5 Brain Health Chair: Kirk Erickson Members: Chuck Hillman, Rich

name charles yan phd katherine rittenbach phd sepideh
Name : Charles Yan, PhD; Katherine

Cost-Effectiveness Analysis of a Randomized Study of Depression Treatment

personalized depression
Personalized Depression Tuan D. Pham

The Recurrence Dynamics of Personalized Depression Tuan D. Pham Saudi Aramco

slide 1 introduction
SLIDE 1 - INTRODUCTION Today we are

SLIDE 1 - INTRODUCTION Today we are going to go through some information about

psychiatric drugs
Psychiatric Drugs: Problems and

Psychiatric Drugs: Problems and Solutions Disclosure I do not have an

investor presentation march 2019 cse vreo disclaimer
Investor Presentation March 2019 CSE:

Investor Presentation March 2019 CSE: VREO Disclaimer CAUTIONARY NOTE